Doramicin (spiramycin) coated tablets 3 000 000 IU №10

$35.00

Manufacturer: Macedonia

Purpose: Spiramycin inhibits bacterial protein synthesis for infections.

SKU: MED57958 Category:

Description

Doramicin (Spiramycin) Coated Tablets 3,000,000 IU №10

Ingredients

Active ingredient: Spiramycin 3,000,000 IU per tablet.

Dosage

Adults: The usual dosage is 3,000,000 IU (1 tablet) twice daily. Consult a healthcare professional for specific dosing instructions.

Indications

Doramicin tablets are indicated for the treatment of bacterial infections sensitive to spiramycin, such as respiratory tract infections, skin and soft tissue infections, and more.

Contraindications

Do not use Doramicin tablets if you are allergic to spiramycin or any other macrolide antibiotics. Consult your doctor before use if you have any underlying medical conditions.

Directions

Take Doramicin tablets orally with a full glass of water. Follow the dosage instructions provided by your healthcare provider or as indicated on the packaging.

Scientific Evidence

Spiramycin, the active ingredient in Doramicin tablets, has been extensively studied for its efficacy in treating various bacterial infections. Research published in the Journal of Antimicrobial Chemotherapy has shown spiramycin to be effective against a wide range of pathogens, making it a valuable option in the management of bacterial infections.

Additional Information

It is important to complete the full course of treatment with Doramicin tablets as prescribed by your healthcare provider, even if you start to feel better before the course is finished. Failure to complete the full course may result in the infection not being fully treated.

Pharmacological Effects: Spiramycin works by inhibiting bacterial protein synthesis, thereby preventing the growth and reproduction of bacteria. This action helps to eradicate the infection and alleviate associated symptoms.

Clinical Trials: Clinical trials have demonstrated the efficacy of Doramicin tablets in the treatment of bacterial infections. A study published in the International Journal of Infectious Diseases showed a high rate of clinical success and tolerability in patients treated with spiramycin for respiratory tract infections.